Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model

2025 · doi:10.64898/2025.12.18.695152
preprint OA: closed CC-BY-NC-ND-4.0
🔓 Open OA copy Full text JSON View at publisher
⚙ AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text ⓘ

This study examined how tirzepatide, a dual GLP-1R/GIPR agonist, may interact with leptin in the context of leptin resistance and limited anti-obesity efficacy. In a clinical trial, baseline circulating leptin levels in patients with obesity correlated with weight loss efficacy, and in diet-induced obesity mice, combined tirzepatide plus leptin produced synergistic weight loss, improved hepatic insulin sensitivity, and increased thermogenic gene expression in brown adipose tissue under thermoneutral conditions. The authors reported that tirzepatide sensitized leptin signaling in hypothalamic POMC neurons and GLP-1R-expressing neurons, including increased POMC neuronal firing via decreased inhibitory postsynaptic input. The paper explicitly frames the findings within obesity models and a leptin-resistance mechanism and does not state a direct limitation beyond this scope. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Leptin resistance limits anti-obesity efficacy. We identified a leptin-sensitizing mechanism through tirzepatide (TZP), a glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonist. Our tirzepatide clinical trial revealed that circulating leptin levels at baseline correlated with weight loss efficacy in patients with obesity, suggesting leptin and tirzepatide could interact to achieve stronger effects on weight loss. Next, we utilized the diet-induced obesity (DIO) mice and demonstrated the synergistic effects of tirzepatide and leptin combination (TZP+Lep) on weight loss. TZP+Lep treatment further improved hepatic insulin sensitivity and upregulated thermogenetic gene expression in brown adipose tissue. Metabolic profiling under thermoneutrality revealed TZP+Lep treatment further reduced food intake and increased energy expenditure. Tirzepatide sensitized leptin signaling in hypothalamic pro-opiomelanocortin (POMC) and GLP-1R expressing neurons. TZP+Lep synergistically increased POMC neuronal firing by decreasing the inhibitory postsynaptic input. Together, our work showed combining tirzepatide and leptin as a potential way for better maintenance of metabolic homeostasis in obesity management. Highlights Tirzepatide and leptin synergistically promote weight loss through reduced food intake and increased energy expenditure. Tirzepatide and leptin synergistically improve insulin sensitivity and metabolic homeostasis with altered hepatic and adipose gene expression. Tirzepatide sensitizes leptin signaling in hypothalamic GLP-1R and POMC neurons. Tirzepatide and leptin synergistically increase POMC neuronal firing by decreasing inhibitory postsynaptic input.
Full text 1,858 characters · extracted from oa-html · click to expand
Abstract Leptin resistance limits anti-obesity efficacy. We identified a leptin-sensitizing mechanism through tirzepatide (TZP), a glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonist. Our tirzepatide clinical trial revealed that circulating leptin levels at baseline correlated with weight loss efficacy in patients with obesity, suggesting leptin and tirzepatide could interact to achieve stronger effects on weight loss. Next, we utilized the diet-induced obesity (DIO) mice and demonstrated the synergistic effects of tirzepatide and leptin combination (TZP+Lep) on weight loss. TZP+Lep treatment further improved hepatic insulin sensitivity and upregulated thermogenetic gene expression in brown adipose tissue. Metabolic profiling under thermoneutrality revealed TZP+Lep treatment further reduced food intake and increased energy expenditure. Tirzepatide sensitized leptin signaling in hypothalamic pro-opiomelanocortin (POMC) and GLP-1R expressing neurons. TZP+Lep synergistically increased POMC neuronal firing by decreasing the inhibitory postsynaptic input. Together, our work showed combining tirzepatide and leptin as a potential way for better maintenance of metabolic homeostasis in obesity management. Highlights Tirzepatide and leptin synergistically promote weight loss through reduced food intake and increased energy expenditure. Tirzepatide and leptin synergistically improve insulin sensitivity and metabolic homeostasis with altered hepatic and adipose gene expression. Tirzepatide sensitizes leptin signaling in hypothalamic GLP-1R and POMC neurons. Tirzepatide and leptin synergistically increase POMC neuronal firing by decreasing inhibitory postsynaptic input. Competing Interest Statement The authors have declared no competing interest. Footnotes ↵‡ Lead contact.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-NC-ND-4.0